Significant association between EGFR-mutated lung adenocarcinoma and past illness from gastric cancer or uterine myoma: Its implication in carcinogenesis

Okudela, Koji; Woo, Tetsukan; Yazawa, Takuya; Ogawa, Nobuo; Tajiri, Michihiko; Masuda, Munetaka; Kitamura, Hitoshi

doi:10.1016/j.lungcan.2009.02.025

« Previous Next »Lung Cancer
Volume 66, Issue 3 , Pages 287-291, December 2009

Significant association between EGFR-mutated lung adenocarcinoma and past illness from gastric cancer or uterine myoma: Its implication in carcinogenesis

Koji Okudela
- Department of Pathology, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, 236-0004, Yokohama, Japan
Tetsukan Woo
- Department of Surgery, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, 236-0004, Yokohama, Japan
Takuya Yazawa
- Department of Pathology, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, 236-0004, Yokohama, Japan
Nobuo Ogawa
- Division of Surgery, Kanagawa Prefectural Cardiovascular and Respiratory Center Hospital, 6-16-1, Tomioka-higashi, Kanazawa-ku, 230-0051, Yokohama, Japan
Michihiko Tajiri
- Division of Surgery, Kanagawa Prefectural Cardiovascular and Respiratory Center Hospital, 6-16-1, Tomioka-higashi, Kanazawa-ku, 230-0051, Yokohama, Japan
Munetaka Masuda
- Department of Surgery, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, 236-0004, Yokohama, Japan
Hitoshi Kitamura
- Department of Pathology, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, 236-0004, Yokohama, Japan
- Corresponding author. Tel.: +81 45 787 2583; fax: +81 45 789 0588.

Received 1 October 2008; received in revised form 8 February 2009; accepted 12 February 2009. published online 13 April 2009.

Abstract

The present study investigated the potential difference between EGFR-mutated lung adenocarcinoma (ADC) and KRAS-mutated ADC in relation to past illness and family history. Among the 153 tumors examined, 33 (21.6%) were EGFR-mutated, and 22 (14.4%) were KRAS-mutated. The EGFR-mutated cases showed a significantly higher prevalence of past illness involving the gastric cancer in males (EGFR 3/8 (37.5%), KRAS 0/13 (0.0%), no mutation (NONE) 1/57 (1.8%); Fisher's exact test, P=0.0064) or uterine myoma in females (EGFR 8/25 (32.0%), KRAS 0/9 (0.0%), NONE 3/41 (7.3%); Fisher's exact test, P=0.0139). No association between the mutations and family history was found. The EGFR-mutated ADC is therefore likely to develop through a distinct carcinogenetic pathway from the others, but genetic backgrounds seemed unlikely to be determinant predisposing to the EGFR-mutated ADC.